Stephen J Freedland
Overview
Explore the profile of Stephen J Freedland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
704
Citations
14353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang T, Wang B, Wei Y, Gan H, Fang B, Li X, et al.
Cell Rep Med
. 2025 Mar;
:102018.
PMID: 40056906
Preclinical studies suggest synergistic effects between androgen receptor inhibitors and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. This phase 2 trial (NCT05223582) evaluates neoadjuvant fuzuloparib plus abiraterone in 35 treatment-naive men with...
2.
Freedland S, Mulhall J, Gleave M, De Giorgi U, Saad F, Rannikko A, et al.
Eur Urol
. 2025 Feb;
PMID: 40016055
EMBARK demonstrated prolonged metastasis-free survival with enzalutamide ± leuprolide versus leuprolide alone for patients with high-risk biochemical recurrence of prostate cancer, with health-related quality of life (HRQoL) maintained. To evaluate...
3.
Axeen S, Chen A, Lakdawalla D, Masia N, Niyazov A, Arondekar B, et al.
JNCI Cancer Spectr
. 2025 Feb;
9(2).
PMID: 39945807
Background: It is important to understand the relationship between drug efficacy measured in randomized clinical trials (RCTs) and real-world drug effectiveness. We estimate how RCT overall survival (OS) and RCT...
4.
DerSarkissian M, Arondekar B, Gupta D, Ivanova J, Niyazov A, Zanardo E, et al.
Clin Genitourin Cancer
. 2025 Jan;
23(2):102291.
PMID: 39813906
Introduction: Racial disparities in prostate cancer (PC) are well studied among Black or African American (BAA) patients but not among Hispanics, a quickly growing US minority group. This study compared...
5.
Castaneda P, Kuhlmann P, Ithisuphalap J, Howard L, Klaassen Z, Rivera L, et al.
Cancer
. 2025 Jan;
131(1):e35684.
PMID: 39748487
Background: Adverse pathology (AP) is often used as an intermediate end point for long-term outcomes in men with prostate cancer (PCa) who are active surveillance candidates. The association between a...
6.
Heard J, Masterson J, Luu M, Gale R, Spiegel B, Freedland S, et al.
Urol Oncol
. 2024 Dec;
PMID: 39674764
Background: Guidelines for prostate cancer treatment in men with limited life expectancy are based on expert opinion. Patient preferences for when to defer treatment based on longevity are unknown. We...
7.
Freedland S, Gleave M, De Giorgi U, Rannikko A, Pieczonka C, Tutrone Jr R, et al.
Future Oncol
. 2024 Dec;
21(5):501-514.
PMID: 39667819
No abstract available.
8.
Agarwal N, George D, Klaassen Z, Sandin R, Butcher J, Ribbands A, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2448707.
PMID: 39652349
Importance: Clarifying the underutilization of treatment intensification (TI) for metastatic castration-sensitive prostate cancer (mCSPC) may improve implementation of evidence-based medicine and survival outcomes. Objective: To investigate physicians' beliefs about TI...
9.
Stock S, Burns M, Waller J, De Hoedt A, Parrish J, Ghate S, et al.
JAMA Netw Open
. 2024 Nov;
7(11):e2445505.
PMID: 39546308
Importance: Prostate cancer (PC) care has evolved rapidly as a result of changes in prostate-specific antigen testing, novel imaging, and newer treatments. The impact of these changes on PC epidemiology...
10.
Zahalka A, Fram E, Garden E, Howard L, Wiggins E, Babar M, et al.
BJUI Compass
. 2024 Nov;
5(11):1095-1100.
PMID: 39539558
Objectives: The objective of this study is to investigate the association between the use of beta-adrenergic antagonist atenolol and risk of pathologic upgrade in patients on active surveillance, considering growing...